Chest
Clinical Investigations in Critical CareAn Early Test of Survival in Patients with the Adult Respiratory Distress Syndrome: The PaO2/FIo2 Ratio and its Differential Response to Conventional Therapy
Section snippets
Study Design
The study design has been reported previously.13 The present study is a retrospective analysis of patients with respiratory failure from a two-step prospective multicenter study designed to determine the effect of PGE, on ARDS. The results of the second step of the study have been reported.13 Both studies were identical in goals, except the first step of the study included 50 patients and accepted patients with multiorgan failure into the trial. When interim analysis revealed no differences in
Demographics
Thirteen centers enrolled 150 patients; 74 patients were randomized to receive placebo. Only the placebo patients are reported in this study. Demographics and selected physiologic variables of the patients are shown in Table 2. Thirty-seven patients survived and 37 patients died for a mortality rate of 50 percent.
Chest X-ray Examination
Results of all chest x-ray films were abnormal at baseline.
Indices of Oxygenation
Figure 1 shows the PaO2/FIo2 by survival for seven days. Table 3 shows the PaO2/FIo2 ratio and their level of significance
DISCUSSION
All patients in this study had ARDS that occurred from trauma, postoperatively, or from sepsis. They had diffuse infiltrates on the chest roentgenogram and had a pulmonary artery wedge pressure (PAWP) ≤18 mm Hg. They were mechanically ventilated and had a resultant partial pressure of oxygen in arterial blood: fractional concentration of oxygen in inspired air (PaO2/FIo2) ratio less than or equal to 150 with no PEEP or less than 200 with PEEP. In this study, we anayzed only placebo patients to
REFERENCES (13)
- et al.
The influence of PEEP on survival of patients in respiratory failure: A retrospective analysis
Am J Med
(1979) - et al.
Gastrointestinal hemorrhage in a respiratory intensive care unit
Chest
(1977) - et al.
Intravascular coagulation associated with the adult respiratory distress syndrome
Am J Med
(1976) - et al.
The adult respiratory distress syndrome
Med Clin North Am
(1987) - et al.
Adult respiratory distress syndrome: Problems and progress
Am Rev Respir Dis
(1985) - et al.
Causes of mortality in patients with the adult respiratory distress syndrome
Am Rev Respir Dis
(1985)
Cited by (142)
Early time-course of respiratory mechanics, mechanical power and gas exchange in ARDS patients
2024, Journal of Critical CarePaO<inf>2</inf>/FiO<inf>2</inf> Deterioration During Stable Extracorporeal Membrane Oxygenation Associates With Protracted Recovery and Increased Mortality in Severe Acute Respiratory Distress Syndrome
2016, Annals of Thoracic SurgeryCitation Excerpt :PF ratio variation within the first week of ARDS diagnosis was also found to have prognostic significance in patients treated without ECMO. Bone and colleagues [19] analyzed PF ratio and its early response to conventional therapy in the placebo group of a large multicenter study. PF ratio was not different at the time of diagnosis of ARDS in survivors compared with nonsurvivors.
Clinical characteristics and outcomes are similar in ARDS diagnosed by oxygen saturation/F io 2 ratio compared with Pa o 2/F io 2 Ratio
2015, ChestCitation Excerpt :Using this approach, we found no association between the severity of ARDS diagnosed by PF ratios and hospital mortality. These findings are concordant with several studies that have shown that the PF ratio measured at the onset of ARDS is not an independent predictor of mortality.20–25 One possible explanation for the lack of the power of the PF ratio to discriminate adverse outcome in ARDS is that the PF ratio is highly variable depending on the ventilator strategy chosen.
Physiologic Markers of Disease Severity in ARDS
2023, Respiratory CareAdjunctive Hydrocortisone Improves Hemodynamics in Critically Ill Patients with Septic Shock: An Observational Study Using Transpulmonary Thermodilution
2023, Journal of Intensive Care Medicine
Manuscript received July 14; revision accepted August 3.
- *
The Prostaglandin E, Study Group consisted of: Bush-Presbyterian-St. Lukes Medical Center, Chicago: Bone RC, Balk R, Szidon P, Hanley M, Jacobs E; Division of Pulmonary Medicine, Maine Medical Center, Portland, ME: Caldwell E, Altaian F, Bagwell S, Cox P, Lambert R, Williams W; University of Minnesota Hospital, Minneapolis: Cerra F, Berlauk J, Gilmour I; Ohio State University, Columbus: Cloutier C, Davies E, Steinburg S; Winthrop University Hospital, Mineola, NY: Fein A, Grant M, Montavani R, Neiderman M, Sklarek H; University of Texas Health Sciences Center, San Antonio, TX: Gaskill H, Levine B; Division of Pulmonary and Critical Care Medicine, Harborview Medical Center, Seattle: Hudson L, Maunder RJ; St. Louis University School of Medicine, Pulmonary Division, St. Louis: Hyers T, Dettenmeier P; Tulane University Medical Center, New Orleans: Kerstein M, Moulder P, Webb W; University of Maryland Hospital, Pulmonary Division, Baltimore: Silverman H, Belzberg H, Mendoza J; Rhode Island Hospital, Department of Surgery, Providence: Slotman G, Burchard K; Geisinger Medical Center, Danville, PA: Smith J, Blackburn J, Burns R; Department of Surgery, University of Texas HSC-Dallas, Dallas: Weigelt J; Coordinating Center, The Upjohn Company, Kalamazoo, MI: Ursprung JJ, Maile M, Wilks NE, Drennen K.